AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29122619 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 207
Study 29122619 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurora A SNP at codon 57
Number of subjects: 207
Study 29122844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR) risk score
Number of subjects: 1196
Study 29122844 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR risk score stratification into low (0/1 point) and high-risk group (≥2 points)
Number of subjects: 1196
Study 29122932 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined CAD-score algorithm
Number of subjects: 1675
Study 29122932 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated CAD-score algorithm (including acoustic features and clinical risk factors)
Number of subjects: 1675
Study 29122932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound-based detection of CAD
Number of subjects: 1675
Study 29122992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion-dependent patients with detectable labile plasma iron levels and high transferrin saturation levels
Number of subjects: 100
Study 29122992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion-independent patients with ringed sideroblasts
Number of subjects: 100
Study 29122992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion-dependent patients
Number of subjects: 100
Study 29123425 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan (60-120 mg/d)
Number of subjects: 135
Study 29124456 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane with low-dose oral cyclophosphamide
Number of subjects: 23
Study 29124506 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB)
Number of subjects: 68
Study 29124506 — intervention group
Group type: COMPARATOR
Intervention: EEG alpha biofeedback with relaxing music and relaxed paced breathing (EEG+)
Number of subjects: 68
Study 29124506 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol after biofeedback sessions
Number of subjects: 68
Study 29124506 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (high-potency inhaled steroid)
Number of subjects: 68
Study 29124992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.15-mg/kg bolus with continuous infusion at 2 µg/kg/min)
Number of subjects: 64
Study 29124992 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 64
Study 29124992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Control)
Number of subjects: 64
Study 29125695 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer combined with clinical pretest probability (PTP)
Number of subjects: 0
Study 29125695 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer
Number of subjects: 0
Study 29125695 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative D-dimer with unlikely PTP
Number of subjects: 0
Study 29125695 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited CUS
Number of subjects: 0
Study 29125695 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CUS
Number of subjects: 0
Study 29126426 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants in the maxilla (six implants each, loaded within 24 hours, definitive restoration after 20-24 weeks)
Number of subjects: 51
Study 29126426 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants in the maxilla
Number of subjects: 51
Study 29126444 — intervention group
Group type: EXPERIMENTAL
Intervention: Easily accessible self-management course for chronic pain
Number of subjects: 21
Study 29126871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (full dose)
Number of subjects: 46
Study 29126871 — intervention group
Group type: COMPARATOR
Intervention: Lumacaftor/ivacaftor (half dose)
Number of subjects: 46
Study 29126871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (half dose increased to full dose)
Number of subjects: 46
Study 29127195 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcatheter contrast injection (MCI) prior to stent retriever deployment
Number of subjects: 51
Study 29127195 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Alberta Stroke Program early CT Score (ASPECTS)
Number of subjects: 51
Study 29127195 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 51
Study 29128389 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT); mean duration 7.8 days; most patients received monotherapy (72.5%)
Number of subjects: 408
Study 29128389 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT)
Number of subjects: 408
Study 29128386 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding biodegradable biliary stents (BDBSs) inserted using endoscopic retrograde cholangiography (ERC)
Number of subjects: 13
Study 29128386 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding biodegradable biliary stents (BDBSs)
Number of subjects: 13
Study 29128828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprospan (betamethasone dual-acting formulation) administered via single-dose intramuscular injection
Number of subjects: 0
Study 29128863 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy patients
Number of subjects: 37
Study 29128863 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 37
Study 29128908 — intervention group
Group type: EXPERIMENTAL
Intervention: cetuximab/TPF followed by chemoradiotherapy
Number of subjects: 50
Study 29129018 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID)
Number of subjects: 0
Study 29129018 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID
Number of subjects: 0
Study 29129256 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous wave-free ratio (iFR)
Number of subjects: 50
Study 29129256 — intervention group
Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 50
Study 29129627 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCHITECT immunoassay for serum AFP measurement
Number of subjects: 530
Study 29129636 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative muscle mRNA expression levels in rectus abdominis (RA)
Number of subjects: 15
Study 29129636 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative muscle protein expression levels in rectus abdominis (RA)
Number of subjects: 15
Study 29129636 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative systemic inflammation
Number of subjects: 15
Study 29129636 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glucose tolerance
Number of subjects: 15
Study 29129636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut permeability
Number of subjects: 15
Study 29129636 — intervention group
Group type: COMPARATOR
Intervention: Bacteraemia
Number of subjects: 15
Study 29130367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Talk question framework
Number of subjects: 74
Study 29130418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 23
Study 29130418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early palliative care intervention)
Number of subjects: 23
Study 29131802 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffolds (BVS)
Number of subjects: 1005
Study 29132305 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerosis cutis
Number of subjects: 223
Study 29132305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ulcers
Number of subjects: 223
Study 29132305 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence associated dermatitis
Number of subjects: 223
Study 29132305 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tears
Number of subjects: 223
Study 29132341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovial H-L® (hybrid formulation of hyaluronic acid)
Number of subjects: 100
Study 29132341 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 100
Study 29132379 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation (SES)
Number of subjects: 8
Study 29133316 — intervention group
Group type: EXPERIMENTAL
Intervention: NKR-2 treatment administered three times with a 2-week interval between each administration.
Number of subjects: 7
Study 29133363 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia group
Number of subjects: 156
Study 29133363 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ABP in preeclampsia group
Number of subjects: 156
Study 29133363 — intervention group
Group type: COMPARATOR
Intervention: Daytime ABP in control group
Number of subjects: 156
Study 29133478 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 51
Study 29133477 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume method
Number of subjects: 169
Study 29133477 — intervention group
Group type: COMPARATOR
Intervention: Dimension method
Number of subjects: 169
Study 29133477 — intervention group
Group type: COMPARATOR
Intervention: Area method
Number of subjects: 169
Study 29133513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) 10 mg/kg IV every 2 weeks combined with Vorinostat (VOR) 400 mg p.o. daily for 7 days on, 7 days off, in a 28-day cycle
Number of subjects: 40
Study 29133757 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 20
Study 29133757 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 20
Study 29133757 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 20
Study 29133757 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 20
Study 29133757 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP and IL-6
Number of subjects: 20
Study 29134133 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit lamp-adapted anterior segmental photography
Number of subjects: 438
Study 29134133 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit lamp-adapted anterior segmental photography with assistance techniques
Number of subjects: 438
Study 29134449 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR1p calculated according to Fleming with sampling at 3 hours
Number of subjects: 96
Study 29134449 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR7p using iohexol clearance with blood sampling at seven time points within 5 hours
Number of subjects: 96
Study 29134606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (500 or 1000 mg) as intravenous infusions
Number of subjects: 140
Study 29134606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 29134606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (500 or 1000 mg)
Number of subjects: 140
Study 29134648 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (0.1 to 17 mg per day)
Number of subjects: 18
Study 29134648 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (therapeutic doses)
Number of subjects: 18
Study 29134664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles
Number of subjects: 0
Study 29134664 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacytidine 25 mg/m2
Number of subjects: 0
Study 29134924 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem® (HLM051)
Number of subjects: 220
Study 29134924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 29135575 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antiretroviral therapy
Number of subjects: 5430
Study 29135685 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral suppression of transient-evoked otoacoustic emissions (TEOAEs) measured in right ears with MOC activation achieved by presenting broadband noise to left ears.
Number of subjects: 16
Study 29135685 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral suppression of TEOAEs
Number of subjects: 16
Study 29136201 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg monotherapy
Number of subjects: 33
Study 29136201 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg plus docetaxel 60 mg/m2
Number of subjects: 33
Study 29136201 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg plus docetaxel 60 mg/m2
Number of subjects: 33
Study 29136201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (selumetinib plus docetaxel)
Number of subjects: 33
Study 29136201 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 50 mg monotherapy
Number of subjects: 33
Study 29136201 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib pharmacokinetic profile
Number of subjects: 33
Study 29136228 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid prescription
Number of subjects: 327
Study 29136228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 327
Study 29136228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related diagnoses
Number of subjects: 327
Study 29136228 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and anxiety
Number of subjects: 327
Study 29136228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 327
Study 29136286 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine
Number of subjects: 72
Study 29136286 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 72
Study 29136317 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept/sirolimus immunotherapy
Number of subjects: 20
Study 29136317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 20
Study 29136317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte repopulation
Number of subjects: 20
Study 29136523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis sedation (group II)
Number of subjects: 300
Study 29137560 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent monetary incentives added to cessation treatments (PV only, PV+Q, PV+CBT) for four weeks after a quit attempt.
Number of subjects: 661
Study 29137560 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriber visit and facilitated quitline (PV+Q) with incentives.
Number of subjects: 661
Study 29137560 — intervention group
Group type: COMPARATOR
Intervention: Prescriber visit for pharmacotherapy only (PV only).
Number of subjects: 661
Study 29137560 — intervention group
Group type: COMPARATOR
Intervention: Prescriber visit and telephone cognitive-behavioral therapy (PV+CBT).
Number of subjects: 661
Study 29138206 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors receiving standard ICU care
Number of subjects: 12000
Study 29138206 — intervention group
Group type: COMPARATOR
Intervention: Control cohort of otherwise seriously ill patients
Number of subjects: 12000
Study 29138245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM) undergoing TAVR
Number of subjects: 47643
Study 29138245 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients (Control group)
Number of subjects: 47643
Study 29138320 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S vaccine (recombinant circumsporozoite protein-based vaccine)
Number of subjects: 0
Study 29138340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor-Modified T Cells
Number of subjects: 0
Study 29138340 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29138569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-300 mg/day for 90 days)
Number of subjects: 299
Study 29138761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Microenvironment of Metastasis (TMEM)
Number of subjects: 600
Study 29138986 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8)
Number of subjects: 637
Study 29138986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 29138986 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (both dose groups)
Number of subjects: 637
Study 29138986 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 637
Study 29139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 60 mg/d for 7 days (DL1; n=6)
Number of subjects: 19
Study 29139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 60 mg/d for 14 days (DL2; n=7)
Number of subjects: 19
Study 29139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 40 mg/d for 14 days (DL-1; n=6)
Number of subjects: 19
Study 29139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib in combination with SOC chemotherapy
Number of subjects: 19
Study 29140542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vWF-Ag levels
Number of subjects: 95
Study 29140542 — intervention group
Group type: EXPERIMENTAL
Intervention: vWF-Ag ≥182% cutoff
Number of subjects: 95
Study 29140542 — intervention group
Group type: EXPERIMENTAL
Intervention: E-selectin correlation with vWF-Ag
Number of subjects: 95
Study 29140548 — intervention group
Group type: EXPERIMENTAL
Intervention: SANGUINATE (SG) infusion, 320 mg/kg, three weekly infusions
Number of subjects: 5
Study 29140548 — intervention group
Group type: EXPERIMENTAL
Intervention: SANGUINATE (SG) infusion
Number of subjects: 5
Study 29140967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular occlusion test (3 min of ischemia and reperfusion) using INVOS
Number of subjects: 0
Study 29140978 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item Test of Adherence to Inhalers (TAI)
Number of subjects: 795
Study 29140978 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-item Morisky Medication Adherence Scale (MMAS-8)
Number of subjects: 795
Study 29140978 — intervention group
Group type: COMPARATOR
Intervention: Comparison of adherence measures (TAI vs MMAS-8)
Number of subjects: 795
Study 29140978 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence levels
Number of subjects: 795
Study 29141463 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 0
Study 29141587 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback using the Marte Meo method
Number of subjects: 278
Study 29141587 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 278
Study 29141603 — intervention group
Group type: EXPERIMENTAL
Intervention: UroMark assay
Number of subjects: 0
Study 29141650 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Number of subjects: 20
Study 29141650 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 29141662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined autologous adipose-derived mesenchymal stem cells (AT-MSCs) and hyaluronic acid (HA) derivative, single intradiscal injection at a dose of 2 × 10.
Number of subjects: 10
Study 29141757 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to specific proteins of microorganisms
Number of subjects: 267
Study 29141757 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection and vaccination with attenuated or inactivated pathogens
Number of subjects: 267
Study 29141853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Number of subjects: 0
Study 29141853 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29141857 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagasic HF
Number of subjects: 2552
Study 29141857 — intervention group
Group type: COMPARATOR
Intervention: Other nonischemic cardiomyopathy
Number of subjects: 2552
Study 29141857 — intervention group
Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy
Number of subjects: 2552
Study 29141948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate plus romidepsin
Number of subjects: 0
Study 29142066 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-CD123A, an antibody-drug conjugate targeting CD123
Number of subjects: 0
Study 29142375 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg for 7 days)
Number of subjects: 73
Study 29142375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 29142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg intravenous induction
Number of subjects: 82
Study 29142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab ~6 mg/kg intravenous induction
Number of subjects: 82
Study 29142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 55.6% intravenous induction
Number of subjects: 82
Study 29142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg subcutaneous maintenance (q12w)
Number of subjects: 82
Study 29142515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg subcutaneous maintenance (q8w)
Number of subjects: 82
Study 29142987 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-avoidance hemodialysis protocol using airless dialysis tubing
Number of subjects: 338
Study 29142987 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-avoidance hemodialysis protocol
Number of subjects: 338
Study 29143287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid (LA) 1200 mg oral administration
Number of subjects: 0
Study 29143287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 0
Study 29143315 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Number of subjects: 0
Study 29143315 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplant of edited haematopoietic stem cells
Number of subjects: 0
Study 29143565 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg once daily (QD)
Number of subjects: 1686
Study 29143565 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg once daily (QD) with N(t)RTI backbone
Number of subjects: 1686